Custom-Made vaccine aims to stop Cancer's return after surgery
NCT ID NCT04912765
First seen Nov 01, 2025 · Last updated Apr 09, 2026 · Updated 23 times
Summary
This study is testing a personalized vaccine designed to teach the body's immune system to recognize and attack leftover cancer cells after surgery. It combines a vaccine made from the patient's own tumor and immune cells with a standard immunotherapy drug (nivolumab). The goal is to prevent the cancer from coming back in people who have had liver tumors surgically removed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center Singapore
RECRUITINGSingapore, 169690, Singapore
Conditions
Explore the condition pages connected to this study.